What's Happening?
Bruker Corporation has announced the European launch of its MyGenius PRO® system at the ESCMID Global 2026 event. This new high-throughput, sample-to-answer molecular diagnostics system is designed to improve the efficiency of infectious disease diagnostics.
Utilizing PCR technology, the MyGenius PRO® allows for continuous loading of samples and supports random-access operation, automating the entire workflow from patient sample to diagnostic result. This system is expected to enhance laboratory efficiency and support higher-volume testing needs. Initially, the system will include assays for Cytomegalovirus, Epstein-Barr virus, and BK virus, with plans to expand the menu to include additional viruses such as HIV-1 and Hepatitis B and C throughout 2026. The development of MyGenius PRO® was a collaborative effort between Bruker, ELITechGroup, and Hitachi High-Tech, with the latter introducing the platform in Japan under a different tradename.
Why It's Important?
The introduction of the MyGenius PRO® system is significant as it represents a major advancement in the field of molecular diagnostics, particularly for infectious diseases. By automating the diagnostic process, the system reduces the time required to obtain results, which is crucial for timely clinical responses and effective infection monitoring. This innovation is particularly beneficial for laboratories dealing with high volumes of tests, as it streamlines workflows and ensures compliance with regulatory standards. The system's ability to handle a wide range of assays also means it can be adapted to meet the evolving needs of healthcare providers, potentially improving patient outcomes and reducing the burden on healthcare systems.
What's Next?
Following its European launch, the MyGenius PRO® system is expected to see rapid adoption in laboratories across the continent, particularly those specializing in infectious disease diagnostics. As the assay menu expands, the system will likely become a critical tool in managing and diagnosing a broader range of viral infections. The collaboration with Hitachi High-Tech suggests potential for further international expansion, particularly in Asia, where the system will be marketed under a different name. This could lead to increased global standardization in diagnostic practices and further advancements in the field of molecular diagnostics.
